GRIFOLS SA

ISIN: ES0171996087 WKN: - Asset Class: Stock



Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Financial figures, Fiscal year: from 01.01. to 31.12.							
Financial figures	2023 Assets Liabilities and equity		2022 Assets Liabilities and equity		2021 Assets Liabilities and equity		
Current assets	6,451,905,000		4,653,587,000		5,510,280,000		
Common stock capital		119,604,000		119,604,000		119,604,000	
Fixed assets	15,002,765,000		17,007,730,000		13,801,384,000		
Equity capital of a company		7,972,485,000		8,457,544,000		8,147,035,000	
Cash and cash equivalents	529,577,000		547,979,000		655,493,000		
Accrued liabilities		116,925,000		110,063,000		24,122,000	
Other assets	-		-		-		
Current liabilities		2,315,604,000		1,955,847,000		3,474,312,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		11,152,774,000		11,232,803,000		7,675,281,000	
Different income		-		-		-	
Other liabilities		814,080,000		891,725,000		9,222,000	
Total assets	21,454,670,000	21,454,670,000	21,661,317,000	21,661,317,000	19,311,664,000	19,311,664,000	

Different income		-		-		-
Other liabilities		814,080,000		891,725,000		9,222,000
Total assets	21,454,670,000	21,454,670,000	21,661,317,000	21,661,317,000	19,311,664,000	19,311,664,000
Balance notes						
Datance notes				2022	2022	2024
				2023	2022	2021
Accounting standard				IFRS	IFRS	IFRS
Employees				23,744	26,326	23,245
Equity ratio				47.16%	49.79%	52.80%
Debt-equity ratio				112.05%	100.84%	89.38%
Others						
				2023	2022	2021
Tax Expense Rate				26.89%	34.76%	29.90%

GRIFOLS SA

ISIN: ES0171996087 WKN: - Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	6,591,977,000	6,063,967,000	4,933,118,000
Net income	59,315,000	208,279,000	182,803,000
EBIT	732,630,000	747,110,000	569,789,000
Operating income before taxes	161,200,000	259,261,000	284,710,000
Cash Flow	208,283,000	-150,000	608,423,000
Net interest income	-571,430,000	-487,849,000	-285,079,000
Research and development expenses	330,551,000	316,845,000	299,570,000
Income taxes	43,349,000	90,111,000	85,126,000
Result from investments in subsidaries, associates and other	62,818,000	101,996,000	65,743,000
Revenues per employee	277,627	230,341	212,223

Chairman of Supervisory Board
Member of Supervisory Board

Members of Management Board				
TI OI				
Thomas Glanzmann	Chairman of Managing Board			
Raimon Grifols Roura	Member of Executive Committee			
Víctor Grífols Deu	Member of Executive Committee			